Canonical microRNA loss drives tumor development, implicating therapeutic efficacy of enoxacin in angiosarcoma
- Bozhi Liu1,2,5,
- Ant Murphy1,2,5,
- Annaleigh Benton1,2,5,
- Lauren Gartenhaus1,2,
- William Budka1,2,
- Juliana M. Bronzini1,2,
- Samuel Hartzler1,
- Madison E. Yates1,
- Alejandra Romero Alzate1,
- Nimod D. Janson1,2,
- Shyaman Jayasundara2,3,
- Sagar Utturkar2,
- Nadia A. Lanman2,4,
- Majid Kazemian2,3 and
- Jason A. Hanna1,2
- 1Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA
- 2Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47906, USA
- 3Department of Biochemistry and Computer Science, Purdue University, West Lafayette, Indiana 47906, USA
- 4Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47906, USA
- Corresponding author: hannaja{at}purdue.edu
-
↵5 These authors contributed equally to this work.
-
Handling editor: Mikiko Siomi
Abstract
Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of Dicer1, a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting Dgcr8, a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of Dgcr8 phenocopies Dicer1 loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.
Keywords
Footnotes
-
Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna.080706.125.
-
Freely available online through the RNA Open Access option.
- Received July 29, 2025.
- Accepted February 5, 2026.
This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.










